Pfizer's 2026 Outlook: Cautious Revenue Forecast Amid Pipeline Development
Pfizer's cautious 2026 outlook with declining COVID-19 sales and patent expirations has led to a reassessment of its valuation, with the stock currently undervalued at $26.43 compared to a fair value of around $29, amid a shift towards high-value biologics and innovative therapies, though regulatory and patent risks remain.